At a Glance

N-methyl cyclazodone (NMC) is a synthetic stimulant that belongs to a small chemical family with a surprisingly eventful history.

1. What the Name Means

The full chemical name reads like jargon, but it unpacks into something simple. Start with cyclazodone, a stimulant studied in the 1960s. Then add one methyl group — a single carbon atom with three hydrogen atoms attached — onto its nitrogen atom. That is what the “N-methyl” refers to: the modification sits on a nitrogen (“N”) atom of the molecule.

Adding a methyl group is a small edit in chemical terms, but it can meaningfully change how a drug behaves in the body — how it is absorbed, how long it lasts, how quickly the liver clears it, and how strongly it interacts with its biological targets. In NMC’s case, the body actually removes that methyl group back off during metabolism, which becomes important for drug testing (Section 7).

Several near-identical molecules share the same core structure and differ only in what hangs off the nitrogen. This is the key to understanding the whole family:

2. Origins: Where It Actually Came From

Textbook accounts often attribute cyclazodone to the American Cyanamid Company. Source tracing indicates that attribution is incorrect.

The originating patents — a British patent published in 1965 (GB 1,005,738) and a U.S. patent granted in 1971 (US 3,609,159, inventors Guidicelli and Najer) — are assigned to Les Laboratoires Dausse of Paris, with French priority dates stretching back to 1963. The American Cyanamid association traces to a different 1967 patent that covers an entirely different chemical class (5-arylidene-2-amino-2-oxazolin-4-ones) described as depressants, not stimulants.

In corporate shorthand, cyclazodone carried the development code LD 3695; the N-methyl compound — NMC — carried the code LD 4202. Neither proceeded through modern clinical development as a medicine.

3. Physical Properties

The originating patent describes the parent compound cyclazodone as a white crystalline solid with a melting point of 139–140 °C, soluble in ethanol and insoluble in water, stable in alkaline conditions and unstable in acid. Independent, modern published characterization of NMC’s physical properties remains sparse.

4. How It’s Thought to Work in the Brain

Here is the plain-language version of stimulant pharmacology.

Neurons communicate by releasing chemical messengers (neurotransmitters) across tiny gaps called synapses. Two that matter for wakefulness and attention are dopamine (signals like “attend to this / keep going”) and norepinephrine (the brain’s “alert” signal). After release, a cleanup system called a reuptake transporter pulls these messengers back into the neuron, ending the signal.

Most classical stimulants work by interfering with that recycling system — either by blocking reuptake (so more messenger stays in the gap) or by promoting release (so more messenger is dumped in). The result either way: higher dopamine and/or norepinephrine activity, producing wakefulness, focus, reduced appetite, and cardiovascular stimulation.

A 2026 evidence review (Vialog’s Cyclazodone Evidence Ledger) checked the major databases and found:

• Zero bioactivity records in ChEMBL for cyclazodone.
• Zero mechanism-of-action entries in the IUPHAR/BPS Guide to Pharmacology for either cyclazodone or pemoline.
• No measured monoamine-transporter or receptor data in PubMed or Europe PMC.

In short: every mechanistic statement about NMC or cyclazodone circulating online — “dopaminergic,” “serotonergic,” “TAAR1 agonist,” and so on — is an inference or a copied claim, not a laboratory measurement.

5. What the Animal and Patent Literature Actually Says

Almost all of the original pharmacology sits in the 1971 Dausse patent, not in peer-reviewed journals, and it concerns the parent cyclazodone:

A single peer-reviewed paper — Segal and colleagues, 1967, indexed under the name “cyclopropylpemoline” — reported that cyclazodone’s stimulatory effects on continuous avoidance behavior resembled those of d-amphetamine. The paper’s abstract is not indexed, so the specific doses and effect sizes aren’t publicly retrievable.

A caution on these sources: patent documents are written to support a claim of novelty, not as clinical evidence, and several of the patent tables omit group sizes or are partly illegible in scans. They also say little about NMC itself, which is a different molecule.

6. How the Body Processes NMC (Toxicokinetics)

The one modern study that measured anything about NMC’s fate in the body was published in 2026 in the journal Metabolites (Gampfer et al.). Its findings:

• Metabolism is simple: NMC is converted — by removing the methyl group (N-demethylation) — into a single detectable metabolite, cyclazodone.
• The key enzyme is CYP2A6: A liver cytochrome P450 enzyme. It accounts for roughly 57% of the conversion at low concentrations, with smaller roles for CYP1A2 (~28%) and CYP2C19 (~15%).
• Protein binding is low-to-moderate: About 36 ± 5% of NMC binds to plasma proteins (~64% unbound).
• Detection nuance: In rats given NMC, neither the parent drug nor the metabolite was detectable by routine GC–MS screening; advanced high-resolution LC–MS found only cyclazodone. In humans this means a urine finding of cyclazodone cannot distinguish whether NMC or cyclazodone was taken, and routine immunoassay drug panels do not detect either.

Two practical implications follow, stated objectively:

1. People vary genetically in CYP2A6 activity, and certain substances inhibit CYP2A6. Slower metabolism of NMC could plausibly raise levels — but no clinical data exist to confirm how much this matters.
2. The 2026 study’s authors noted that its results come from in vitro models and rats; the essential human numbers (absorption, peak concentration, and half-life) remain undetermined.

7. Reported Effects (Anecdotal, Not Verified)

Because no clinical study exists, the only descriptions of NMC’s subjective effects come from community reports compiled on harm-reduction platforms. These are self-reported, unverified, and subject to all the biases of anonymous internet reports; they are included here for completeness, not as established fact.

Self-reported oral dose ranges circulating on one widely referenced wiki place a “threshold” around 5 mg and a “common” range around 10–20 mg, with a reported total duration of roughly 9–12 hours (onset 20–35 min; peak 5–7 h). Again: these are community figures, not measurements, and are not a recommendation.

Reported subjective effects (anecdotal) include:

• Stimulation and wakefulness — often described as “smooth” relative to classical stimulants.
• Focus and motivation enhancement — the main reason the compound is discussed in “nootropic” circles; comparisons are frequently made to methylphenidate (Ritalin).
• Anorectic effect (reduced appetite).
• Increased heart rate or blood pressure (anecdotally reported; not quantified).
• Mild euphoria at higher doses; limited prosocial/empathogenic effects in some reports.
• Side effects / Comedown: Insomnia, headache, dry mouth, sweating, nausea, anxiety, and a “comedown” characterized by fatigue and low mood in other reports.

Community sources also note that tolerance develops and that the compound shows cross-tolerance with other dopaminergic stimulants — meaning regular use of one reduces the acute response to the others. None of this has been formally studied for NMC. Several factors make community anecdotes especially unreliable for this compound: unknown actual identity and purity of the purchased powder; unmeasured doses (eyeballed or “scooped” powders); confirmation bias; and small, self-selected samples.

8. Toxicology: The One Documented Case

In 2022, clinicians reported the case that gave toxicologists their first structured look at NMC’s toxicity profile (Basile et al., presented at the American Academy of Clinical Toxicology). A 38-year-old man had dissolved NMC powder — purchased online as “pure” product — in water, reporting roughly 5 grams total over five days (about 1 g/day). For context, this is many multiples of any dose range discussed in community sources (Section 7), and orders of magnitude beyond typical prescribed stimulant doses.

Treatment was entirely supportive: intravenous fluids, lorazepam (a benzodiazepine) for the movements and autonomic overactivity, sodium bicarbonate (which shortened the widened QRS), and magnesium. Laboratory confirmation via high-resolution mass spectrometry identified cyclazodone in urine — the expected metabolite of NMC — with no pemoline, amphetamines, or other unexpected drugs. Symptoms resolved by hospital day 3, with CK and ALT trending down.

Reading the case fairly: it is a single, heavily overdosed individual who also took prescribed fluoxetine and aripiprazole for bipolar disorder, so it cannot define how NMC behaves at other doses or in other people.

9. Regulatory & Anti-Doping Status

Cyclazodone was expressly named on the 2007 WADA Prohibited List but is not named on the 2026 list. However, the list’s stimulant section closes with a catch-all covering substances with “a similar chemical structure or similar biological effect(s),” meaning unlisted stimulants can still fall within anti-doping rules for competitive athletes.

10. What the Scientific Record Does and Doesn’t Contain

Assembled honestly, the entire modern research record for this compound is thin:

Published work that measures something about NMC or cyclazodone:

• A 2026 toxicokinetic study (metabolism, involved enzymes, protein binding) — the only modern biological study.
• A 2022 human toxicity case report.
• Two analytical-chemistry papers (2017, 2019) covering detection methods and supplement screening — these measure how to detect the molecule, not what it does.
• A 1967 rat behavioral note (indexed without an abstract) and 1960s patent data.

Things that do not exist:

• No human clinical trial, pharmacokinetic study, or dose-finding study.
• No measured molecular target (no transporter or receptor data).
• No established half-life, clearance, or therapeutic window in humans.

12. Summary

N-methyl cyclazodone is a synthetic stimulant in the pemoline family, first patented with its parent compound in the 1960s and recently reappearing as an unapproved, unscheduled powder sold online. Its pharmacology is almost entirely inferred rather than measured; its metabolism is now partially characterized (rapid conversion to cyclazodone, primarily via the CYP2A6 enzyme); and its human evidence base consists of community anecdotes plus one heavily overdosed case that produced a distinctive stimulant-toxicity syndrome.

Whether it is “safer,” “more effective,” or “different” from approved stimulants is, at present, an unanswered empirical question — one that no published study has been designed to settle.